Frontage Laboratories, Inc. has completed the acquisition of Nucro-Technics Inc., a pharmaceutical contract research organization that conducts analytical chemistry, microbiology, toxicology, bioanalytical, and stability sample storage and testing services. It also provides consulting services, especially in quality control and assurance as well as in Natural Health Product Regulations.  
 
Nucro-Technics, located in Toronto, Canada, operates in a state-of-the-art 60,000 sq.-ft. facility with expertise in testing both large and small molecules designed to treat various medical conditions. Nucro-Technics conducts studies for major pharmaceutical, biotech, and medical device companies, as well as smaller organizations including industry trade groups and academia.

Nucro-Technics has successfully developed and validated numerous methods, as well as participated in providing comprehensive IND packages to clients for regulatory submissions. Nucro-Technics, an ISO 9001:2015 certified organization, conducts studies that are in compliance with GLP and GMP regulations.
 
“It is with great pleasure that I welcome the extraordinary Nucro-Technics team to the Frontage family,” said Dr. Abdul Mutlib, CEO of Frontage.  “Nucro-Technics has been recognized as a leader in the Canadian CRO market for over 50 years, and its unparalleled client services is a perfect match for the culture of Frontage Laboratories.  This acquisition not only significantly strengthens our presence in Canada, but also will enable the combined organization to offer a more expansive suite of services to clients across the globe.  We are looking forward to partnering with the Nucro team to deliver the world-class expertise that clients have come to expect from us.”
 
“I’m delighted to announce that we will be partnering with Frontage Labs for the next phase of Nucro Technics’ growth journey. Since founding the business in 1970, we’ve worked hard to become the North American boutique in pre-clinical and drug product release testing services. Partnering with Frontage Labs marks an exciting chapter in the evolution of our efforts to support and accelerate pharmaceutical research and development,” said John Fanaras of Nucro Technics.